PATENT COOPERATION TREATY

INTERNATIONAL SEARCHING	AUTHORIT	Υ				
To: BRYAN H. DAVIDSON NIXON & VANDERHYE P.C. 901 NORTH GLEBE ROAD			PCT			
ARLINGTON, VA 22203			WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY			
·			(PCT Rule 43bis.1)			
			Date of mailing (day/month/year) 2 3 JAN 2007			
Applicant's or agent's file referen	ce		FOR FURTHER ACTION See paragraph 2 below			
International application No.	Inter	national filing date ((day/month/year) Priority date (day/month/year)			
PCT/US05/01138		anuary 2005 (13.01.2		13 January 2004 (13.01.2004)		
International Patent Classification	(IPC) or both	national classificati	on and IPC	13 January 2004 (13.01.2004)		
IPC: A61F 2/02(2006.01) A0 USPC: 424/423	51F 2/02(200	6.01)	·			
Applicant	· · · · · · · · · · · · · · · · · · ·					
ROYER BIOMEDICAL, INC.				•		
1. This opinion contains indicati	ons relating to	the following items	5:			
Box No. I Basi	of the opinion	on				
Box No. II Prior	ity					
Box No. III Non-	establishmen	t of opinion with reg	ard to novelty, inve	entive step and industrial applicability		
Box No. IV Lack	of unity of in	vention				
Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement						
Box No. VI Certa	in documents	cited	•			
Box No. VII Certa	in defects in t	the international appl	lication			
Box No. VIII Certa	in observation	ns on the internation	al application	·		
2. FURTHER ACTION						
If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.						
If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.						
For further options, see Form PCT/ISA/220.						
3. For further details, see notes to Form PCT/ISA/220.						
Name and mailing address of the IS Mail Stop PCT, Atm: ISA/U: Commissioner for Patents		Date of completic	on of this opinion 06 (21.12.2006)	Carlos A. Azpuru / Walson		
P.O. Box 1450 Alexandria, Virginia 22313-1	450			Telephone No. 703 309 1225		
Facsimile No. (571) 273-3201		1		Telephone No. 703-308-1235		

Form PCT/ISA/237 (cover sheet) (April 2005)

International application No.

PCT/US05/01138

ROX L	to. I Basis of this opinion
1. With	regard to the language, this opinion has been established on the basis of:
\boxtimes	the international application in the language in which it was filed
	a translation of the international application into, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and oil 1(b)).
2 With	
inver	regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed ation, this opinion has been established on the basis of:
a.	type of material
	a sequence listing
	table(s) related to the sequence listing
b.	format of material
	on paper
	in electronic form
c.	time of filing/furnishing
	contained in the international application as filed.
	filed together with the international application in electronic form.
	furnished subsequently to this Authority for the purposes of search.
3. 🗍	In addition in the ages that many then are surely as a second of the sec
٠. ـــا	In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the
	application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4. Additi	onal comments:
	·

Form PCT/ISA/237(Box No. I) (April 2005)

Form PCT/ISA/237 (Box No. V) (April 2005)

International application No. PCT/US05/01138

Statement			
Novelty (N)	Claims 1-39		YI
	Claims NONE		N(
Inventive step (IS)	Claims 1-39		YE
•••••••••••••••••••••••••••••••••••••••	Claims NONE		NC
Industrial applicability (IA)	Claims 1-39		YE
A STATE OF THE STA	Claims NONE		NC
Citations and explanations:			<u> </u>
tims 1-39 meet the criteria set out in PCT Article imed composition comprising an inorganic salt, a extable used in the treatment of various diseases	and organic polymer and a	a non-aqueous solvent which	y suggest the instantly may be combined to form
ims 1-39 meet the criteria set out in PCT Article	•		he subject matter claimed (
made or used in industry.			···
	,		
	,		

PATENT COOPERATION TREATY

INTERNATIONAL SEA	RCHING AUTH	ORITY		·		
To: BRYAN H. DAVIDSON NIXON & VANDERHYE P.C. 901 NORTH GLEBE ROAD			PCT WRITTEN OPINION OF THE			
ARLINGTON, VA 22203				IONAL SEARCHING AUTHORITY		
·			(PCT Rule 43bis.1)			
			Date of mailing (day/month/year) 2 3 JAN 2007			
Applicant's or agent's file reference			FOR FURTHER ACTION			
1729-35			See paragraph 2 below			
International application	No.	International filing date (day/month/year)	/month/year) Priority date (day/month/year)		
PCT/US05/01138	reification (IDC)	13 January 2005 (13.01.2 or both national classificati		13 January 2004 (13.01.2004)		
	006.01) A61F 2/0		on and IPC			
USPC: 424/423						
Applicant						
ROYER BIOMEDICAL	, INC.					
1. This opinion contain	s indications rela	ating to the following items	:			
Box No. I	Basis of the	opinion		· *,·		
Box No. II	Priority			·		
Box No. III						
Box No. IV		y of invention				
Box No. V						
Box No. VI						
Box No. VII	Box No. VII Certain defects in the international application					
Box No. VIII	Certain obse	rvations on the internation:	al application			
2. FURTHER ACTI	ON					
If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("PEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.						
If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220.						
3. For further details, see notes to Form PCT/ISA/220.						
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Date of completed to the ISA/US 21 December 20			on of this opinion 06 (21.12.2006)	Carlos A. Azpuru / Walson		
Alexandria, Virgir Facsimile No. (571) 273-3				Telephone No. 703-308-1235		

Form PCT/ISA/237 (cover sheet) (April 2005)

International application No.

PCT/US05/01138

Box N	o. I Basis of this opinion
_	regard to the language, this opinion has been established on the basis of:
\boxtimes	the international application in the language in which it was filed
L	a translation of the international application into, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and etc.1(b)).
2. With inven	regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed tion, this opinion has been established on the basis of:
a.	type of material
	a sequence listing
	table(s) related to the sequence listing
b.	format of material
	on paper
	in electronic form
c.	time of filing/furnishing
	contained in the international application as filed.
	filed together with the international application in electronic form.
	furnished subsequently to this Authority for the purposes of search.
3. 🗌	In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4. Additi	onal comments:
	•
٠	
DCYE/	(SAD27(Roy No. D. (April 2005)

Form PCT/ISA/237(Box No. I) (April 2005)

International application No.
PCT/US05/01138

Box No. V Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement					
1. Statement					77
Novelty	(N)	Claims	1-39		YES
		Claims	NONE		
Inventive	e step (IS)	Claims	1-39		YES
			NONE		NO
Industria	al applicability (IA)	Claims	1 20		VPC
mousura	r applicability (IA)		NONE		YES NO
•	<u> </u>				
. Citations and exp	lanations:				
laimed composition of	comprising an inorgani	Article 33(2)-(3), beca ic salt, and organic poly seases when combined	mer and a กดก-คดบ	es not teach or fairly cous solvent which n	suggest the instantly aay be combined to form a
claims 1-39 meet the ce made or used in ind	criteria set out in PCT lustry.	Article 33(4), and thus	have industrial app	licability because the	subject matter claimed ca
	•				
•	•				
			٠		

Form PCT/ISA/237 (Box No. V) (April 2005)